Visionix and iCare Officially Merge Portfolios to Create a More Connected Eye Care Technology Ecosystem.
Visionix and iCare have officially combined portfolios following Revenio's acquisition of Visionix, marking a significant development in the global ophthalmic technology market. The move brings together a broad range of diagnostic, imaging, screening, and workflow solutions, creating one of the most comprehensive eye care technology portfolios available today.
The integration reflects a growing industry focus on connected healthcare ecosystems, where clinicians can access multiple technologies and clinical capabilities through a more unified platform. By combining complementary strengths across diagnostics, retinal imaging, refraction, optical coherence tomography (OCT), software, AI-enabled workflows, and telehealth capabilities, the expanded portfolio is designed to support eye care professionals across the full patient journey.
Expanding Access to Integrated Eye Care Technologies
As eye care providers continue to face increasing demand for efficiency, accuracy, and streamlined clinical workflows, integrated technology platforms are becoming increasingly important.
The combined Visionix and iCare offering brings together technologies that support:
- Comprehensive eye examinations
- Retinal imaging and disease detection
- Refraction and vision assessment
- Optical coherence tomography (OCT)
- Screening and monitoring programmes
- Clinical workflow optimisation
- AI-supported diagnostic processes
- Telehealth and remote care capabilities
By consolidating these technologies within a single ecosystem, practices may benefit from improved interoperability, more efficient patient management, and enhanced clinical decision-making.
Supporting the Evolution of Modern Eye Care
The merger highlights a broader trend within ophthalmology and optometry towards connected diagnostic platforms that enable practitioners to move seamlessly between screening, diagnosis, monitoring, and patient management.
As healthcare providers increasingly adopt digital technologies, the ability to integrate data, imaging, diagnostics, and workflow management into a cohesive environment is becoming a key differentiator for technology manufacturers and clinical practices alike.
The addition of Visionix's capabilities strengthens Revenio's presence across multiple ophthalmic segments while expanding its reach into areas such as OCT, advanced imaging, and tele-optometry. Combined with iCare's established portfolio in tonometry, retinal imaging, perimetry, and disease monitoring, the result is a broader offering capable of supporting a diverse range of clinical environments.
What This Means for the Eye Care Industry
The combination of Visionix and iCare represents more than a portfolio expansion. It signals the continued evolution of eye care technology towards integrated platforms that connect devices, clinical data, imaging, diagnostics, and patient workflows within a single ecosystem.
As optometrists, ophthalmologists, and optical retailers seek solutions that improve efficiency while supporting better patient outcomes, demand for connected technologies is expected to continue growing. The newly combined portfolio positions Revenio to play an increasingly important role in shaping the future of digital eye care and ophthalmic innovation.
With diagnostics, imaging, OCT, AI-enabled workflows, software, and telehealth capabilities now united under one portfolio, the merger creates a stronger foundation for future innovation across the global eye care market.